Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Related Keywords

Norway ,Iceland ,Villejuif ,France General ,France ,Liechtenstein ,United States ,Northern Ireland ,Craigavon ,United Kingdom ,America ,Isabella Zinck ,Karim Fizazi ,Fran Rodrigues ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Gustave Roussy ,Alina Levchuk ,Twitter ,European Commission ,World Health Organization ,International Communications ,Novartis Us External Communications ,Novartis External Communications ,International Prospective ,Novartis ,Exchange Commission ,Us National Library Of Medicine ,Novartis Pharmaceuticals ,Innovative Medicines International ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Medicinal Products ,Human Use ,Medical Oncology ,Marie France Tschudin ,Chief Commercial Officer ,Prostate Cancer ,Phenotypic Precision Medicine ,Metastatic Castration Resistant Prostate ,Health Organization ,Nucl Med ,Receptor Directed Therapy ,Combination With Soc ,Versus Soc Alone ,Adult Male Patients With ,Investegate Announcements ,Investegate Company Announcements ,Ovartis Ag Chf0 50 Regd ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,